Background/Aims: Puumala virus (PUUV) infection leads to nephropathia epidemica (NE), especially in endemic areas in Central Europe. The clinical course of NE is characterized by acute kidney injury (AKI) with thrombocytopenia followed by polyuria to a different degree. The prevalence of polyuria and its associated risk factors have not been reported in a large cohort of NE patients. Methods: Clinical and laboratory data during the acute phase of the disease were obtained from the medical reports and files of 335 patients who received in-hospital treatment during acute hantavirus infection. Comprehensive statistical models were developed to estimate the probability of polyuria. Results: The median age at diagnosis was 47 years (interquartile range, IQR 40-59) and 48% of the patients developed polyuria with a urinary output of 5,100 ml/day (IQR 4,200-7,300). The hospital stay was significantly longer in the polyuric group compared to the nonpolyuric group [8 days (IQR 6-10) vs. 6 days (IQR 5-8); p = 0.04]. Using logistic regression analysis, male gender (odds ratio, OR = 1.6; 95% confidence interval, CI 1.05-2.58; p = 0.03), oliguria/anuria during NE (OR = 2.56; 95% CI 1.65-4.01; p < 0.001), severe AKI (OR = 1.87; 95% CI 1.22-2.9; p < 0.001), and hematuria (OR = 1.78; 95% CI 1.02-3.15; p = 0.04) were significantly associated with the development of polyuria. In a multivariate model, the probability of polyuria was 0.19 (SEM ± 0.05) in female patients presenting with mild/moderate AKI without anuria/oliguria. Conclusions: Almost 50% of hospitalized NE patients developed polyuria, which was associated with a prolonged hospital stay. The probability of the development of polyuria was lowest in female patients with mild/moderate, non-oliguric/anuric AKI.

Journal Section:
Original Paper
Keywords:
Hantavirus, Puumala virus, Hemorrhagic fever with renal syndrome, Nephropathia epidemica, Polyuria
1.
Bi Z, Formenty PB, Roth CE: Hantavirus infection: a review and global update. J Infec Dev Ctries 2008;2:3-23.
[PubMed]
https://doi.org/10.3855/jidc.317
2.
Kruger DH, Ulrich RG, Hofmann J: Hantaviruses as zoonotic pathogens in Germany. Dtsch Ärztebl Int 2013;110:461-467.
[PubMed]
https://doi.org/10.3238/arztebl.2013.0461
3.
Hantavirus pulmonary syndrome in visitors to a national park - Yosemite Valley, California, 2012. MMWR Morb Mortal Wkly Rep 2012;61:952.
[PubMed]
4.
Schmaljohn CS, Dalrymple JM: Analysis of Hantaan virus RNA: evidence for a new genus of bunyaviridae. Virology 1983;131:482-491.
[PubMed]
https://doi.org/10.1016/0042-6822(83)90514-7
5.
Kruger DH, Ulrich R, Lundkvist AA: Hantavirus infections and their prevention. Microbes Infect 2001;3:1129-1144.
[PubMed]
https://doi.org/10.1016/S1286-4579(01)01474-5
6.
Lee HW, van der Groen G: Hemorrhagic fever with renal syndrome. Prog Med Virol 1989;36:62-102.
[PubMed]
7.
Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA: Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006;19:437-442.
[PubMed]
https://doi.org/10.1097/01.qco.0000244048.38758.1f
8.
Peters CJ, Simpson GL, Levy H: Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999;50:531-545.
[PubMed]
https://doi.org/10.1146/annurev.med.50.1.531
9.
Watson DC, Sargianou M, Papa A, Chra P, Starakis I, Panos G: Epidemiology of hantavirus infections in humans: a comprehensive, global overview. Crit Rev Microbiol 2013;40:261-272.
[PubMed]
https://doi.org/10.3109/1040841X.2013.783555
10.
Boone I, Wagner-Wiening C, Reil D, Jacob J, Rosenfeld UM, Ulrich RG, Lohr D, Pfaff G: Rise in the number of notified human hantavirus infections since October 2011 in Baden-Württemberg, Germany. Euro Surveill 2012;17:20180.
[PubMed]
11.
Vapalahti O, Mustonen J, Lundkvist A, Henttonen H, Plyusnin A, Vaheri A: Hantavirus infections in Europe. Lancet Infect Dis 2003;3:653-661.
[PubMed]
https://doi.org/10.1016/S1473-3099(03)00774-6
12.
Braun N, Haap M, Overkamp D, Kimmel M, Alscher MD, Lehnert H, Haas CS: Characterization and outcome following Puumala virus infection: a retrospective analysis of 75 cases. Nephrol Dial Transplant 2010;25:2997-3003.
[PubMed]
https://doi.org/10.1093/ndt/gfq118
13.
Krautkramer E, Zeier M, Plyusnin A: Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int 2013;83:23-27.
[PubMed]
https://doi.org/10.1038/ki.2012.360
14.
Latus J, Kitterer D, Kimmel M, Alscher MD, Braun N: The case fever, myalgia, visual disorders, and acute kidney failure in a pregnant woman - diagnosis: severe acute hantavirus infection. Kidney Int 2013;84:629-631.
[PubMed]
https://doi.org/10.1038/ki.2013.49
15.
Kruger DH, Schonrich G, Klempa B: Human pathogenic hantaviruses and prevention of infection. Hum Vaccin 2011;7:685-693.
[PubMed]
https://doi.org/10.4161/hv.7.6.15197
16.
Cosgriff TM: Hemorrhagic fever with renal syndrome: four decades of research. Ann Intern Med 1989;110:313-316.
[PubMed]
https://doi.org/10.7326/0003-4819-110-4-313
17.
Rose BD, Post TW: Clinical Physiology of Acid-Base and Electrolyte Disorders, ed 5. New York, McGraw-Hill, 2001, pp 748, 767.
18.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (adqi) group. Crit Care 2004;8:R204-R212.
[PubMed]
https://doi.org/10.1186/cc2872
19.
Huttunen NP, Makela S, Pokka T, Mustonen J, Uhari M: Systematic literature review of symptoms, signs and severity of serologically confirmed nephropathia epidemica in paediatric and adult patients. Scand J Infect Dis 2011;43:405-410.
[PubMed]
https://doi.org/10.3109/00365548.2011.559666
20.
Rasche FM, Uhel B, Kruger DH, Karges W, Czock D, Hampl W, Keller F, Meisel H, von Muller L: Thrombocytopenia and acute renal failure in Puumala hantavirus infections. Emerg Infect Dis 2004;10:1420-1425.
[PubMed]
https://doi.org/10.3201/eid1008.031069
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.